Cargando…
Renal cell carcinoma: An update for the practicing urologist
Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinica...
Autores principales: | Pal, Sumanta K., Bergerot, Paulo, Figlin, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Second Military Medical University
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730695/ https://www.ncbi.nlm.nih.gov/pubmed/29264115 http://dx.doi.org/10.1016/j.ajur.2015.04.012 |
Ejemplares similares
-
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
por: Salgia, Meghan, et al.
Publicado: (2017) -
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010) -
Pathology Update for Urologists
por: Iczkowski, Kenneth A., et al.
Publicado: (2011) -
Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma
por: Staehler, Michael, et al.
Publicado: (2021) -
Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)